A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues

Vaccines

Bushra Ayat Meghla¹  Ali Azam Talukder¹  Md. Irfan Jawad¹  Taslima Akter Tisha¹  Nafisa Azmuda¹  Jaykaran Charan²  Shahana Sharmin³  Mohd. Raeed Jamiruddin⁴  Shahad Saif Khandker⁴  Mohib Ullah Khondoker⁴  Md. Ahsanul Haq⁴  Nihad Adnan⁴  Brian Godman⁵  Mainul Haque⁶ 

[1] Department of Microbiology, Jahangirnagar University, Savar 1342, Bangladesh;Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur 342005, India;Department of Pharmacy, BRAC University, Dhaka 1212, Bangladesh;Gonoshasthaya-RNA Molecular Diagnostic & Research Center, Dhanmondi, Dhaka 1205, Bangladesh;Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G1 1XQ, UK;The Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia (National Defence University of Malaysia), Kem Perdana Sugai Besi, Kuala Lumpur 57000, Malaysia;

关键词: clinical trials;    COVID-19 vaccines;    systematic review;    inactivated vaccines;    mRNA vaccines;    nanoparticle-based vaccines;   

DOI  :  10.3390/vaccines9121387

来源: DOAJ

【 摘 要 】

COVID-19 vaccines are indispensable, with the number of cases and mortality still rising, and currently no medicines are routinely available for reducing morbidity and mortality, apart from dexamethasone, although others are being trialed and launched. To date, only a limited number of vaccines have been given emergency use authorization by the US Food and Drug Administration and the European Medicines Agency. There is a need to systematically review the existing vaccine candidates and investigate their safety, efficacy, immunogenicity, unwanted events, and limitations. The review was undertaken by searching online databases, i.e., Google Scholar, PubMed, and ScienceDirect, with finally 59 studies selected. Our findings showed several types of vaccine candidates with different strategies against SARS-CoV-2, including inactivated, mRNA-based, recombinant, and nanoparticle-based vaccines, are being developed and launched. We have compared these vaccines in terms of their efficacy, side effects, and seroconversion based on data reported in the literature. We found mRNA vaccines appeared to have better efficacy, and inactivated ones had fewer side effects and similar seroconversion in all types of vaccines. Overall, global variant surveillance and systematic tweaking of vaccines, coupled with the evaluation and administering vaccines with the same or different technology in successive doses along with homologous and heterologous prime-booster strategy, have become essential to impede the pandemic. Their effectiveness appreciably outweighs any concerns with any adverse events.

【 授权许可】

Unknown